Iterum Therapeutics plc Ordinary Share (ITRM) Dividend History

Iterum Therapeutics plc is a clinical-stage pharmaceutical company focused on developing and commercializing innovative antibiotics for serious and life-threatening infections. The company aims to address the growing problem of antibiotic resistance by creating new therapies to treat resistant bacterial infections. Its pipeline includes oral and intravenous formulations designed to combat multidrug-resistant pathogens.

Fitzwilliam Court, 1st Floor, Dublin 2, L2, D02 YW24
Phone: (872) 225-6077
Website: https://www.iterumtx.com

Dividend History

Iterum Therapeutics plc Ordinary Share currently does not pay dividends

Company News

  • ITRM Reports Results

    Iterum Therapeutics reported a Q2 2025 loss of $0.13 per share, higher than expected, as the company prepares for the commercial launch of its oral antibiotic ORLYNVAH™ for urinary tract infections. The company has secured manufacturing agreements and extended its cash runway into 2026.

    The Motley Fool
    Featured Companies: PFE
  • Iterum Therapeutics Reports Second Quarter 2025 Financial Results

    Iterum Therapeutics plans to launch ORLYNVAH™, its first branded antibiotic for uncomplicated urinary tract infections, in August 2025. The company has partnered with EVERSANA for commercialization and has sufficient cash runway into 2026.

    GlobeNewswire Inc.
    Featured Companies: PFE
  • Iterum (ITRM) Plans Early Submission of UTI Drug NDA, Stock Up

    Iterum (ITRM) stock rises as the company gears up to submit a regulatory application to the FDA seeking approval for oral sulopenem to treat adult women with uUTIs ahead of schedule.

    Zacks Investment Research
    Featured Companies: ACET ADMA FGEN
  • Insiders Buying Iterum Therapeutics And 3 Other Stocks Under $3

    The Dow Jones index closed higher by over 100 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Iterum Therapeutics The Trade: Iterum Therapeutics plc (NASDAQ: ITRM) Director Michael W Dunne acquired a total of 25,000 shares an average price of $1.40. To acquire these shares, it cost around $35,000. What’s Happening: Iterum Therapeutics recently regained compliance with Nasdaq Bid Price Rule for continued listing. What Iterum ...

    Benzinga
    Featured Companies: NTWK RVP
  • Penny Stocks To Buy Now? 7 Hot Stocks Under $1 To Watch

    More penny stocks to watch under $1 The post Penny Stocks To Buy Now? 7 Hot Stocks Under $1 To Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

    PennyStocks
Page data last updated 09/08/2025 06:32:04 UTC